Boundless Bio Statistics

Total Valuation

Boundless Bio has a market cap or net worth of $32.27 million. The enterprise value is -$26.17 million.

Market Cap	32.27M
Enterprise Value	-26.17M

Important Dates

The next estimated earnings date is Wednesday, May 6, 2026, before market open.

Earnings Date	May 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Boundless Bio has 22.41 million shares outstanding. The number of shares has increased by 31.65% in one year.

Current Share Class	22.41M
Shares Outstanding	22.41M
Shares Change (YoY)	+31.65%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	1.72%
Owned by Institutions (%)	38.35%
Float	16.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.33
P/TBV Ratio	0.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.74, with a Debt / Equity ratio of 0.50.

Current Ratio	8.74
Quick Ratio	8.58
Debt / Equity	0.50
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -46.69% and return on invested capital (ROIC) is -22.96%.

Return on Equity (ROE)	-46.69%
Return on Assets (ROA)	-21.86%
Return on Invested Capital (ROIC)	-22.96%
Return on Capital Employed (ROCE)	-43.97%
Weighted Average Cost of Capital (WACC)	1.13%
Revenue Per Employee	n/a
Profits Per Employee	-$2.08M
Employee Count	28
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.04% in the last 52 weeks. The beta is -0.25, so Boundless Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.25
52-Week Price Change	-2.04%
50-Day Moving Average	1.23
200-Day Moving Average	1.21
Relative Strength Index (RSI)	58.03
Average Volume (20 Days)	468,016

Short Selling Information

The latest short interest is 145,151, so 0.65% of the outstanding shares have been sold short.

Short Interest	145,151
Short Previous Month	15,345
Short % of Shares Out	0.65%
Short % of Float	0.89%
Short Ratio (days to cover)	0.36

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-63.55M
Pretax Income	-58.20M
Net Income	-58.20M
EBITDA	-62.30M
EBIT	-63.55M
Earnings Per Share (EPS)	-$2.60

Full Income Statement

Balance Sheet

The company has $107.58 million in cash and $49.04 million in debt, giving a net cash position of $58.55 million or $2.61 per share.

Cash & Cash Equivalents	107.58M
Total Debt	49.04M
Net Cash	58.55M
Net Cash Per Share	$2.61
Equity (Book Value)	98.65M
Book Value Per Share	4.40
Working Capital	97.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$46.66 million and capital expenditures -$546,000, giving a free cash flow of -$47.21 million.

Operating Cash Flow	-46.66M
Capital Expenditures	-546,000
Depreciation & Amortization	1.25M
Net Borrowing	n/a
Free Cash Flow	-47.21M
FCF Per Share	-$2.11

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Boundless Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.65%
Shareholder Yield	-31.65%
Earnings Yield	-179.74%
FCF Yield	-145.80%

Analyst Forecast

The average price target for Boundless Bio is $4.00, which is 177.78% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	177.78%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-11.31%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1